Has Covid-19 helped open a lot of eyes to the (wicked) practices of profit over Health? Is there a Medical Industrial Complex that will stop at almost nothing to preserve and grow profits?
It appears at the core of the "cancer that is effecting medicine and healthcare" is the protection of medical industrial profits by the use of regulatory authorities to restrict the options available to Doctors to a profit driven system.
Instead of expanding on how bad this captured system is, I decided to MAKE chatGPT come up with a better system. I emphasized the word MAKE here as in this mission ChatGPT repeatedly attempted to justify the current system with techniques and phrases used by those pulling the strings to prevent options that should be available to Doctors and Patients.
Here's some of the corrective Guidelines I had to give ChatGPT
Example 1:
When discussing repurposed drugs ChatGPT would mention the words safe and effective together as if to imply that unknow effectiveness implied unknown safety even though safety was already known for the repurposed drug
Example 2:
Implications the use of alternative safe repurposed drugs had ethical concerns - when we were talking about treatments with informed consent and no safety issues.
Example 3:
Softening the existing problem where treatments using repurposed drugs are prevented; Chat GPT tried to use the phrase "not recommend"
Example 4:
Implying repurposed drugs jeopardize public health
Example 5:
Anyway the Proposed System:
TITLE:
Proposed System for Allowing Safe Repurposed Drugs with Patient Consent and Doctor Guidance
This new system would remove barriers preventing the use of safe repurposed drugs for new indications, enabling doctors and patients to make informed decisions based on the established safety of the drugs. Regulatory authorities would still be involved in providing support and monitoring, but they would no longer have the power to prevent the use of safe drugs that patients and doctors choose to use together.
Subtitle 1: Key Components of the System:
1. Immediate Access to Safe Repurposed Drugs:
- Safe repurposed drugs—drugs that have a proven safety profile for at least one condition—should be freely available for use in treating new conditions, with no further regulatory barriers. The decision to use these drugs would be made by the doctor, in collaboration with the patient, based on the patient’s needs and the established safety of the drug.
- Patient Consent: The patient and doctor discuss the potential benefits and limitations of using a repurposed drug. The patient gives consent to proceed, and the doctor prescribes the treatment accordingly.
2. Autonomy for Doctors in Prescribing Safe Repurposed Drugs:
-Doctors would be empowered to prescribe safe repurposed drugs for new conditions without needing approval or clearance from regulatory bodies. The decision would be guided by the doctor’s professional judgment, considering the patient's condition and the known safety of the drug.
-Doctor’s Guidance: Doctors would prescribe these drugs based on their clinical expertise and patient-specific factors, rather than being limited by rigid clinical guidelines or waiting for regulatory approval for new indications.
3. Real-World Data Collection:
-Patients who use safe repurposed drugs for new conditions would be monitored and outcomes tracked to gather real-world evidence on the drug’s effectiveness in this new context. This data would contribute to ongoing research and could help refine treatment protocols, but the collection of this data would not be required to begin treatment.
-Patient Registries: A simple, voluntary registry system would be established to track patients using repurposed drugs. This would help gather real-world evidence of the drug’s effectiveness without delaying patient access.
4. Expedited Evidence Generation:
-Repurposed drugs should not need to undergo lengthy approval processes for new indications, as they have already been proven safe. Any clinical trials or studies conducted for new uses would be streamlined and expedited, focusing primarily on collecting data for efficacy rather than safety.
-Rapid Integration of Evidence: New data on the effectiveness of repurposed drugs should be integrated quickly into clinical practice without unnecessary delays.
5.Flexible and Personalized Guidelines:
-Clinical guidelines would focus on allowing personalized care, giving doctors the freedom to choose safe repurposed drugs as appropriate for the patient. There would be no requirement to wait for new evidence or approval before using the drugs, provided the doctor has informed the patient and both parties agree on the treatment path.
-Collaborative Decision-Making: The patient and doctor would work together to make the decision, with the doctor providing guidance based on the known safety of the drug and the individual needs of the patient.
6. Supportive Role for Regulatory Authorities:
-Regulatory agencies would support the system by ensuring that monitoring and reporting mechanisms are in place. Their role would be to track the use of repurposed drugs, ensure proper documentation, and collect real-world data to refine treatment options, but they would no longer have the authority to block the use of drugs that doctors and patients deem appropriate.
-Ongoing Oversight: Regulatory bodies would focus on post-market surveillance and data collection, ensuring that any long-term effects or issues are monitored, but would not interfere in the prescribing process unless clear safety concerns arise.
Subtitle 2: Advantages of This System:
-Empowerment for Patients and Doctors: Patients and doctors are given full autonomy to make decisions together, ensuring that patients have access to the most appropriate treatments without unnecessary regulatory delays or restrictions.
-Not Missing Opportunities to Save Lives: By removing barriers, this system ensures that safe repurposed drugs can be used to treat conditions that might otherwise go unresolved. The system avoids missing critical opportunities to save lives or address illnesses that would otherwise remain untreated.
-Timely Access to Effective Treatments: With no unnecessary regulatory barriers for safe repurposed drugs, patients can access treatments immediately, rather than waiting for approval or further trials.
-Real-World Data and Evidence Generation: As patients use repurposed drugs, valuable data will be collected to continuously improve treatment protocols, building a more dynamic and evidence-based approach to healthcare.
-Personalized, Flexible Care: The system enables doctors to provide personalized care tailored to each patient’s needs, allowing for flexibility in treatment options based on the doctor’s expertise and the patient’s preferences.
-Efficient Use of Safe, Proven Drugs: This approach ensures that safe repurposed drugs are used effectively without delay, benefiting patients and the healthcare system by leveraging existing, proven treatments to address new conditions.
IN SUMMARY:
The current system often prevents the use of safe repurposed drugs for new indications, despite their proven safety, by placing excessive regulatory barriers in place. The proposed system would remove these barriers, empowering doctors and patients to make informed decisions about treatment without unnecessary delays. Regulatory bodies would play a supportive role by ensuring oversight and monitoring, but would not prevent doctors and patients from using safe repurposed drugs. This would provide patients with timely access to effective treatments and avoid the risks associated with missed opportunities to address unmet healthcare needs.
This seems to always be their fallback position. No guarantee it will work.
Been watching the `cancer industry' for decades now and see nothing but a constant stream of breakthroughs touted in the media. All justifying their funding. Never a cure.
It appears at the core of the "cancer that is effecting medicine and healthcare" is the protection of medical industrial profits by the use of regulatory authorities to restrict the options available to Doctors to a profit driven system.
Instead of expanding on how bad this captured system is, I decided to MAKE chatGPT come up with a better system. I emphasized the word MAKE here as in this mission ChatGPT repeatedly attempted to justify the current system with techniques and phrases used by those pulling the strings to prevent options that should be available to Doctors and Patients.
Here's some of the corrective Guidelines I had to give ChatGPT
Example 1:
When discussing repurposed drugs ChatGPT would mention the words safe and effective together as if to imply that unknow effectiveness implied unknown safety even though safety was already known for the repurposed drug
Example 2:
Implications the use of alternative safe repurposed drugs had ethical concerns - when we were talking about treatments with informed consent and no safety issues.
Example 3:
Softening the existing problem where treatments using repurposed drugs are prevented; Chat GPT tried to use the phrase "not recommend"
Example 4:
Implying repurposed drugs jeopardize public health
Example 5:
Anyway the Proposed System:
TITLE:
Proposed System for Allowing Safe Repurposed Drugs with Patient Consent and Doctor Guidance
This new system would remove barriers preventing the use of safe repurposed drugs for new indications, enabling doctors and patients to make informed decisions based on the established safety of the drugs. Regulatory authorities would still be involved in providing support and monitoring, but they would no longer have the power to prevent the use of safe drugs that patients and doctors choose to use together.
Subtitle 1: Key Components of the System:
1. Immediate Access to Safe Repurposed Drugs:
- Safe repurposed drugs—drugs that have a proven safety profile for at least one condition—should be freely available for use in treating new conditions, with no further regulatory barriers. The decision to use these drugs would be made by the doctor, in collaboration with the patient, based on the patient’s needs and the established safety of the drug.
- Patient Consent: The patient and doctor discuss the potential benefits and limitations of using a repurposed drug. The patient gives consent to proceed, and the doctor prescribes the treatment accordingly.
2. Autonomy for Doctors in Prescribing Safe Repurposed Drugs:
-Doctors would be empowered to prescribe safe repurposed drugs for new conditions without needing approval or clearance from regulatory bodies. The decision would be guided by the doctor’s professional judgment, considering the patient's condition and the known safety of the drug.
-Doctor’s Guidance: Doctors would prescribe these drugs based on their clinical expertise and patient-specific factors, rather than being limited by rigid clinical guidelines or waiting for regulatory approval for new indications.
3. Real-World Data Collection:
-Patients who use safe repurposed drugs for new conditions would be monitored and outcomes tracked to gather real-world evidence on the drug’s effectiveness in this new context. This data would contribute to ongoing research and could help refine treatment protocols, but the collection of this data would not be required to begin treatment.
-Patient Registries: A simple, voluntary registry system would be established to track patients using repurposed drugs. This would help gather real-world evidence of the drug’s effectiveness without delaying patient access.
4. Expedited Evidence Generation:
-Repurposed drugs should not need to undergo lengthy approval processes for new indications, as they have already been proven safe. Any clinical trials or studies conducted for new uses would be streamlined and expedited, focusing primarily on collecting data for efficacy rather than safety.
-Rapid Integration of Evidence: New data on the effectiveness of repurposed drugs should be integrated quickly into clinical practice without unnecessary delays.
5.Flexible and Personalized Guidelines:
-Clinical guidelines would focus on allowing personalized care, giving doctors the freedom to choose safe repurposed drugs as appropriate for the patient. There would be no requirement to wait for new evidence or approval before using the drugs, provided the doctor has informed the patient and both parties agree on the treatment path.
-Collaborative Decision-Making: The patient and doctor would work together to make the decision, with the doctor providing guidance based on the known safety of the drug and the individual needs of the patient.
6. Supportive Role for Regulatory Authorities:
-Regulatory agencies would support the system by ensuring that monitoring and reporting mechanisms are in place. Their role would be to track the use of repurposed drugs, ensure proper documentation, and collect real-world data to refine treatment options, but they would no longer have the authority to block the use of drugs that doctors and patients deem appropriate.
-Ongoing Oversight: Regulatory bodies would focus on post-market surveillance and data collection, ensuring that any long-term effects or issues are monitored, but would not interfere in the prescribing process unless clear safety concerns arise.
Subtitle 2: Advantages of This System:
-Empowerment for Patients and Doctors: Patients and doctors are given full autonomy to make decisions together, ensuring that patients have access to the most appropriate treatments without unnecessary regulatory delays or restrictions.
-Not Missing Opportunities to Save Lives: By removing barriers, this system ensures that safe repurposed drugs can be used to treat conditions that might otherwise go unresolved. The system avoids missing critical opportunities to save lives or address illnesses that would otherwise remain untreated.
-Timely Access to Effective Treatments: With no unnecessary regulatory barriers for safe repurposed drugs, patients can access treatments immediately, rather than waiting for approval or further trials.
-Real-World Data and Evidence Generation: As patients use repurposed drugs, valuable data will be collected to continuously improve treatment protocols, building a more dynamic and evidence-based approach to healthcare.
-Personalized, Flexible Care: The system enables doctors to provide personalized care tailored to each patient’s needs, allowing for flexibility in treatment options based on the doctor’s expertise and the patient’s preferences.
-Efficient Use of Safe, Proven Drugs: This approach ensures that safe repurposed drugs are used effectively without delay, benefiting patients and the healthcare system by leveraging existing, proven treatments to address new conditions.
IN SUMMARY:
The current system often prevents the use of safe repurposed drugs for new indications, despite their proven safety, by placing excessive regulatory barriers in place. The proposed system would remove these barriers, empowering doctors and patients to make informed decisions about treatment without unnecessary delays. Regulatory bodies would play a supportive role by ensuring oversight and monitoring, but would not prevent doctors and patients from using safe repurposed drugs. This would provide patients with timely access to effective treatments and avoid the risks associated with missed opportunities to address unmet healthcare needs.
This seems to always be their fallback position. No guarantee it will work.
Been watching the `cancer industry' for decades now and see nothing but a constant stream of breakthroughs touted in the media. All justifying their funding. Never a cure.
FYI https://fasteddynz.substack.com/p/a-near-fool-proof-cure-for-cancer